U.S.-based NeoStem Signs Twin Agreements To Provide Stem Cell Treatments To Chinese Hospitals
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The New York-headquartered biopharmaceutical firm NeoStem Inc has signed twin agreements to provide a leading-edge stem cell-based orthopedic therapy to two Chinese hospitals